Molecular and immunological biomarkers to predict IVIg response

Trends in Molecular Medicine

Volumn 21, Issue 3, 2015, Pages 145-147

  Galeotti, Caroline ^a,b,c,d   Kaveri, Srini V ^a,b,c,e,f   Bayry, Jagadeesh ^a,b,c,e,f  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

Cytokines; Fc receptor; Guillain Barr syndrome; Immune thrombocytopenia; Intravenous immunoglobulin; Kawasaki disease

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; IMMUNOGLOBULIN; FC RECEPTOR;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; HUMAN; IMMUNOLOGY; INFLAMMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREDICTION; SHORT SURVEY; TREATMENT RESPONSE; DNA METHYLATION; DRUG RESISTANCE; FEMALE; GENETICS; MALE;

DNA METHYLATION; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RECEPTORS, IGG;

EID: 84924609109     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.01.005     Document Type: Short Survey

References (10)

1. Sleeper L.A., et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J. Pediatr. 2011, 158:831-835. e833.
2. Abe J., et al. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J. Allergy Clin. Immunol. 2008, 122:1008-1013. e1008.
3. Fury W., et al. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Hum. Immunol. 2010, 71:865-873.
4. Wang Y., et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum. 2013, 65:805-814.
5. Khor C.C., et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat. Genet. 2011, 43:1241-1246.
6. Shrestha S., et al. Role of activating FcgammaR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. Circ. Cardiovasc. Genet. 2012, 5:309-316.
7. Kuo H.C., et al. DNA methylation array identifies genomic hypomethylation of FCGR2A in the susceptibility of Kawasaki disease and intravenous immunoglobulin resistance. Arthritis Rheumatol. 2014, Published online December 2, 2014. 10.1002/art.38976.
8. Shrestha S., et al. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. J. Allergy Clin. Immunol. 2011, 128:677-680.
9. Mouzaki A., et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 2002, 100:1774-1779.
10. Mori I., et al. Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barre syndrome. PLoS ONE 2008, 3:e2109. 10.1371/journal.pone.0002109.